ReviewNeuropsychiatric disease and treatment2025
Efficacy and Tolerability of Viloxazine Compared to Placebo on Emotional, Behavioral, and Executive Functioning in Children and Adolescents with ADHD: A Systematic Review and Meta-Analysis.
Review in Neuropsychiatric disease and treatment, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Attention Deficit Hyperactivity Disorder (ADHD) can lead to significant long-term consequences, including emotional and behavioral problems, in addition to difficulties with executive function. While stimulant medications are commonly used to treat ADHD, concerns about the risk of drug abuse have led to interest in non-stimulant options including viloxazine. This study aims to evaluate the effectiveness of viloxazine in improving emotional, behavioral, and executive function in children and adolescents with ADHD, focusing on age-related differences in treatment outcomes, symptom presentation, and medication tolerability to inform tailored approaches to treatment. Methods: This systematic review assesses the effectiveness of viloxazine in children and adolescents with ADHD. A comprehensive search of electronic databases, including Cochrane Controlled Trials Register, CINAHL, ClinicalTrials.gov, Embase, PubMed, and Scopus, was conducted for randomized controlled trials (RCTs) published by May 4, 2024. Studies were included if they reported mean changes in emotional and behavioral problems and executive function. The review was registered under PROSPERO ID CRD42022302673. Results: Viloxazine consistently improved emotional, behavioral, and executive function in children with ADHD, with similar but less consistent trends observed in adolescents. Both age groups experienced side effects such as somnolence, decreased appetite, and fatigue, necessitating careful monitoring to enhance tolerability and reduce dropout rates. Discussion: The limited number of eligible RCTs presents challenges in drawing definitive conclusions. While viloxazine shows the potential to improve ADHD symptoms and executive functioning, its acceptability and tolerability vary between children and adolescents. Further research is essential to explore the long-term safety and efficacy of viloxazine, particularly in adolescents, and to more completely understand the mechanisms of its action. Future studies should also compare viloxazine with other non-stimulant treatments to optimize ADHD management strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.